(DumbMoney.)

Explore the latest updates and key analyses on companies, markets, and industry trends.


Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Pulse Biosciences (PLSE) | September 2, 2025

By Liam Parker

image

Pulse Biosciences announced the successful procedures in a multicenter study for treating benign thyroid nodules.

The study aims to reduce symptoms caused by BTNs while preserving thyroid function.

Patients will be evaluated at multiple follow-up visits for safety, targeted volume reduction, and quality of life improvements.

Significant Milestone Achieved

Successful procedures mark a key milestone for Pulse Biosciences and the medical community.

Patient-Friendly Procedure

The study aims to reduce symptoms caused by BTNs without complete thyroid removal.

Continued Progress in Clinical Studies

Positive outcomes in early procedures highlight the commitment to advancing patient treatment.

  • The first successful procedures in the PRECISE-BTN study demonstrate early positive results.
  • Pulse Biosciences' nsPFA technology shows potential for improving patient quality of life through non-thermal cell clearance.
  • The study's focus on safety, symptom reduction, and quality of life assessments indicates a comprehensive approach to patient care.

Pulse Biosciences' successful procedures in the PRECISE-BTN study pave the way for innovative and patient-friendly treatments for benign thyroid nodules, marking a significant step forward in healthcare innovation.